诺诺蛋白调节人类三阴性乳腺癌细胞中的免疫反应
Carmelina Antonella Iannuzzi1, Iris Maria Forte1, Marianna Tomeo2
1Department of Breast and Thoracic Oncology, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.
International journal of molecular sciences
|September 13, 2025
概括
在三阴性乳腺癌 (TNBC) 中,NONO蛋白抑制免疫反应. 抑制NONO激活cGAS/STING通路,增强抗瘤免疫力,并提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 三重阴性乳腺癌 (TNBC) 提出了重大治疗挑战和死亡率.
- 对于RNA结合蛋白NONO在癌症免疫信号传递中的作用基本上是未知的.
- NONO与瘤发生有关,因此需要对其更广泛的功能进行研究.
研究的目的:
- 调查NONO在调节TNBC免疫信号通路中的作用.
- 为了确定NONO调制是否影响cGAS/STING通路和免疫反应.
- 探索NONO作为增强TNBC抗瘤免疫力的潜在治疗标.
主要方法:
- 在MDA-MB-231 TNBC细胞中使用短毛RNA (shRNA) 和化学抑制剂 (R) -SKBG-1来调节NONO表达.
- 评估了细胞质DNA积累,微核形成和cGAS/STING通路的激活标记.
- 测量了TBK1的酸化,NF-κB的核定位,以及促炎性基因转录 (例如,CCL5).
主要成果:
- NONO枯竭诱导了细胞质DNA的积累和微核的形成.
- 激活了cGAS/STING通路,通过增加cGAS/STING激活和TBK1酸化来证明.
- 证实了NONO的免疫抑制功能,在NONO抑制后显示了增强的NF-κB激活和促炎基因表达.
结论:
- 在TNBC中,NONO作为一个关键的免疫抑制调节剂.
- 抑制NONO通过cGAS/STING通路增强了抗瘤免疫反应.
- 在组合疗法中,NONO抑制剂可能是有益的,特别是对于具有特定缺陷或低免疫透率的瘤.
相关概念视频
Receptor Downregulation in MVBs
2.8K
Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR...
2.8K
The Nucleolus
10.3K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
10.3K
NF-κB-dependent Signaling Pathway
9.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.8K
Negative Regulator Molecules
38.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.3K
Regulation of Angiogenesis and Blood Supply
3.3K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.3K
mTOR Signaling and Cancer Progression
4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
4.6K


